revumenib + iadademstat

revumenib + iadademstat is an investigational all-oral epigenetic combination for acute leukemias that pairs revumenib, a selective menin–KMT2A interaction inhibitor, with iadademstat, a covalent, highly selective inhibitor of lysine-specific demethylase 1 (LSD1/KDM1A). Revumenib blocks the interaction between menin and KMT2A fusion or NPM1-mutant oncoproteins to disrupt leukemogenic transcriptional programs, while iadademstat inhibits LSD1’s catalytic and scaffolding functions to promote differentiation and depletion of leukemic stem and progenitor cells.[2][3][7][8][14] The combination is conceptually aimed at deeply reprogramming aberrant transcription and epigenetic states in genetically defined subsets of acute myeloid leukemia and related acute leukemias; revumenib is being developed by Syndax, and iadademstat by Oryzon.[3][7][14][16]